- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Fast Track Designation for Dapagliflozin; California Advocates Against Vaping; Measles Cases Fading
The FDA grants fast track designation of AstraZeneca's dapagliflozin; California to conduct public awareness campaign against vaping; no new US measles cases.
FDA Grants Fast Track Designation for Farxiga in Heart Failure
California Governor Warns Public of Vaping Danger
US Measles Outbreak Fading
AstraZeneca announced yesterday that the FDA has granted fast track designation for the development of dapagliflozin, sold as Farxiga, to reduce the risk of cardiovascular (CV) death or worsening of heart failure in adults with heart failure and reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). The announcement follows last month’s FDA fast track designation of dapagliflozin to delay the progression of renal failure and prevent CV and renal death in patients with chronic kidney disease. The decision was based on 2 phase 3 trials, DAPA-HF and DELIVER, which investigated the role of dapagliflozin in patients with heart failure and HFrEF or HFpEF.Governor Gavin Newsom, D-California, announced yesterday that the state will spend $20 million on a public awareness campaign about the dangers of vaping nicotine and cannabis products, according to the Los Angeles Times. The move comes amid the nationwide rise in vaping-related illnesses and will increase efforts to stop the sale of illicit products. California has reported at least 63 cases, and 1 death, in association to these vaping-related lung illnesses. Many cases have been linked to the use of cannabis-based oils, but the CDC reports that some affected individuals were vaping nicotine products. The public awareness campaign will tackle all forms of vaping, added Newsom.The United States’ worst measles epidemic in 27 years may be in its final stages as no new cases were reported in the last week, according to The Associated Press. The epidemic emerged last year when travelers who had become infected overseas spread the disease to unvaccinated people, with most cases reported in Orthodox Jewish communities in and around New York City. This year, 1241 cases have been reported which has threatened to remove the disease elimination status held by the United States for over 2 decades. If no new cases occur, the epidemic will be set to end on or near September 30.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Intermountain Healthcare and Story Health Partner to Optimize Rural Heart Failure Care
February 7th 2023On this episode of Managed Care Cast, we speak with Tom Stanis, CEO and cofounder of Story Health, and Phillip Wood, Intermountain Ventures program director, on how their partnership came about, how it is going so far, and the future of their collaboration.
Listen
The weight loss drug semaglutide showed significant cardiovascular benefits; Texas and Florida are restricting the promotion of COVID-19 vaccines; some Ohio legislators are seeking to block courts from interpreting the state’s recently passed constitutional amendment that created a right to abortion.
Read More
What We’re Reading: AI Heart Attack Detection; FDA Menthol Ban; Shooting Survivor Care Obstacles
November 7th 2023Artificial intelligence (AI) could help detect heart attack risk signs and prevent sudden cardiac death; Advocates demand the Biden administration finalize the proposed FDA ban on menthol cigarettes; Gun violence survivors and their families have many ongoing medical needs.
Read More
